2017
DOI: 10.18579/jpcrkc/2017/16/2/116433
|View full text |Cite
|
Sign up to set email alerts
|

Solid Lipid Nanoparticles- An Innovative Approach for Improving the Solubility and Bioavailability

Abstract: The purpose of this study is to give a general review on solid lipid nanoparticles (SLNs) as a novel drug carrier for improving the solubility and bioavailability of drugs. Approach: Among the various colloidal drug carriers, SLNs have been emerged as next generation drug delivery system for incorporating lipophilic drugs. They are relatively nontoxic and nonirritant. The review insight on the various methods of preparation, characterization and also the application of SLNs for improving the solubility and bio… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2021
2021
2021
2021

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(2 citation statements)
references
References 2 publications
0
2
0
Order By: Relevance
“…6,7,82 DSC works on the fact that different lipids modifications have different melting points and melting energy. 5 Infrared Radiation spectroscopy and Raman spectroscopy both techniques are used to find out the structural properties of lipids.…”
Section: Crystallinity and Lipid Modificationsmentioning
confidence: 99%
See 1 more Smart Citation
“…6,7,82 DSC works on the fact that different lipids modifications have different melting points and melting energy. 5 Infrared Radiation spectroscopy and Raman spectroscopy both techniques are used to find out the structural properties of lipids.…”
Section: Crystallinity and Lipid Modificationsmentioning
confidence: 99%
“…Insoluble drug delivery strategies: review of recent advances and business prospects [3][4] Solid lipid nanoparticles (SLNs) as a colloidal carrier have proved their potential by surpassing the limitations of other carriers from the early 1990s. 5 Several potent formulations do not show success in therapy, leading to an increase in the rejection rate of API from the FDA. Factors that contribute to treatment failure include low absorption and fast metabolism, indiscriminate drug distribution leading to insufficient drug concentration (e.g.…”
Section: Introductionmentioning
confidence: 99%